NCT01975337View on ClinicalTrials.gov

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Kidney Failure, Chronic
Interventions
DRUG

Alisporivir

Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)

Trial Locations (1)

32809

Novartis Investigative Site, Orlando

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY